Have atrial fibrillation and atrial flutter been reported with zanubrutinib?

Atrial fibrillation and atrial flutter have occurred with zanubrutinib (Brukinsa), particularly in patients with cardiac risk factors, hypertension or acute infections and those aged ≥65 years; patients should be monitored for signs and symptoms and managed appropriately.